Clinical Trials Logo
  1. Home
  2. Myeloproliferative Neoplasms
  3. NCT05936359

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

Myeloproliferative Neoplasms Clinical Trial

Official title:
A Phase 1, Open-Label, Multicenter Study of INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

Clinical Trial Summary

This study is being conducted to evaluate the safety, tolerability, and dose-limiting toxicity (DLT) and determine the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDE) of INCA033989 administered as a monotherapy or in combination with ruxolitinib in participants with myeloproliferative neoplasms.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05936359
Study type Interventional
Source Incyte Corporation
Contact Incyte Corporation Call Center (US)
Phone 1.855.463.3463
Email medinfo@incyte.com
Status Recruiting
Phase Phase 1
Start date September 25, 2023
Completion date February 29, 2028
View Details
See also
  Status Clinical Trial Phase
Terminated NCT04866056 - Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF. Phase 1/Phase 2
Completed NCT02084563 - Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms Phase 2
Recruiting NCT04339400 - A Study of TQ05105 Tablets in Subjects With Myeloproliferative Neoplasms Phase 1
Completed NCT02125318 - A Study of Anagrelide Controlled Release (GALE-401) in Patients With High Platelet Counts Due to Bone Marrow Disorders Phase 2
Not yet recruiting NCT06291987 - Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation Phase 1
Recruiting NCT03314974 - Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders Phase 2
Completed NCT03075826 - A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms Phase 2
Recruiting NCT02823210 - Clinical and Therapeutic Impact of Molecular Markers in Myeloproliferative Disorders
Not yet recruiting NCT06313593 - A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms Phase 1
Active, not recruiting NCT05444530 - A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms Phase 1
Active, not recruiting NCT03912064 - A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT Phase 1
Terminated NCT02393248 - Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) Phase 1/Phase 2
Completed NCT02076191 - Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML Phase 1/Phase 2
Active, not recruiting NCT04761770 - Study of a Geriatric Assessment to Plan a Treatment Approach for Older People With Various Blood Disorders Phase 2
Recruiting NCT06034002 - A Study to Evaluate INCA033989 Administered in Participants With Myeloproliferative Neoplasms Phase 1
Completed NCT00949364 - Pomalidomide in Patients With Myeloproliferative Neoplasms in Fibrotic Stage Phase 2
Completed NCT00053196 - Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer Phase 2
Terminated NCT01668173 - HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET Phase 2
Active, not recruiting NCT03618485 - Registry of Patients With MPNs in Taiwan